IceCure Medical Ltd. entered into a Securities Purchase Agreement on June 17, 2026, to issue and sell pre-funded warrants to purchase 1,833,334 ordinary shares, Series D and Series E warrants to purchase up to 1,833,334 shares each, at a combined purchase price of $2.9999 per warrant. The offering is expected to raise approximately $5.5 million in gross proceeds to be used for working capital and general corporate purposes. The company also agreed to amend existing warrants to reduce their exercise price from $16.50 to $3.00 per share. IceCure Medical Ltd. is a medical technology company specializing in breast cancer cryoablation.
